• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biotronik touts doctors’ survey responses for Magmaris drug-eluting scaffold

March 30, 2017 By Sarah Faulkner

Biotronik touts doctors' survey responses for Magmaris drug-eluting scaffoldBiotronik touted data today from its Magnesium 1,000 program, which provided doctors with an early post-market opportunity to evaluate the company’s new resorbable Magmaris magnesium scaffold. More than 98% of physicians reported that the scaffolds successfully deployed, according to the data, and that it performed well compared to the leading polymeric scaffold, Biotronik said.

The program began in June last year and included more than 400 physicians in 237 hospitals across 32 countries. Biotronik asked the participating physicians to rate their personal experiences of acute performance with Magmaris and to compare their experiences with the leading polymeric scaffold for each case.

More than 95% of physicians rated Magmaris’ performance as good or very good, with similar results as it relates to trackability, pushability, crossability and confromability.

In 72% of cases, the Magmaris scaffold was compared with the leading polymeric scaffold and in 70-78% of cases, Magmaris was rated better or slightly better in categories of acute performance, including vessel conformability.

“The scaffold’s exceptional trackability and crossability help to facilitate smoother delivery,” Dr. Gregor Leibundgut, Kantonsspital Baselland in Liestal, Switzerland, said in prepared remarks. “This makes the implantation easier and safer for the doctor and the patient.”

Biotronik said the scaffold’s backbone is more flexible than its competitor, enabling good vessel conformability. It also boasts an electro-polished metallic surface, which lessens friction and eases lesion crossing, according to the company.

“With the Magnesium 1,000 program, we wanted to ensure that physicians could achieve the best possible results with Magmaris,” Biotronik’s VP of marketing for the vascular intervention biz, Dr. Alexander Uhl, said. “This means providing physicians with a clear protocol for implantation.”

The Magmaris limus-eluting scaffold resorbs in approximately 1 year and is indicated for patients with de novo lesions that match the available scaffold sizes.

Filed Under: Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Biotronik

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS